Alpha Tau Medical, a cancer pharmaceutical company, went public via a SPAC merger with Healthcare Capital, a special purposes acquisition company, in a $1bn deal. "We thank our investors, both new joiners as well as those who have supported us for years, who continue to demonstrate their faith in the company and its leadership. The completion of this transaction will allow the company to realize its vision and implement the clinical development plans and construction of our manufacturing plants around the world, in order to bring hope to millions of patients around the world," Uzi Sofer, Alpha Tau CEO and Chairman.